Close Menu

This story has been updated with additional comments from Elaine Mardis during the plenary clinical trials session of the AACR annual meeting. The headline has also been updated.

NEW YORK − BioNTech's personalized cancer vaccine RO7198457 combined with the PD-L1 inhibitor atezolizumab (Genentech's Tecentriq) appears to be active and well tolerated in patients with solid tumors, according to new data presented at the second virtual session of the American Association for Cancer Research's annual meeting last Friday.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.